The Lupus Foundation of America (LFA) marked the 10th year of its Evening of Hope Gala by honoring leaders in the fight against lupus while raising funds to advance the nonprofit’s mission. Hundreds of advocates and community members gathered in New York City to recognize the efforts…
News
Oral treatment with cenerimod shows promising safety and efficacy in people with mild to moderate systemic lupus erythematosus (SLE), including reduced disease activity and lower levels of immune cells in the blood, according to data from a Phase 2 trial. The research, “First Use of Cenerimod, a Selective…
Adding investigational anifrolumab to standard therapy lowers disease activity, limits the need for corticosteroids, and eases skin symptoms in people with moderate to severe systemic lupus erythematosus (SLE), a Phase 3 clinical trial shows. Trial results were discussed in a presentation titled “A Phase 3…
Adding Gazyva (obinutuzumab) to standard-of-care treatment more than doubles the proportion of complete kidney responses in people with proliferative lupus nephritis, a Phase 2 study shows. A Phase 3 study of Gazyva in lupus nephritis is expected to start next year. The findings were presented at two meetings…
The Lupus Foundation of America (LFA) is partnering with health informatics company Prometheus Research to develop a next-generation data platform, set to launch next year, to help advance lupus research. LFA will use the platform to expand its Research.forME Lupus Registry, which was launched in 2017…
Adding anifrolumab to standard-of-care treatment significantly reduced disease activity, corticosteroid use, and severity of skin lesions in people with moderate-to-severe systemic lupus erythematosus (SLE), according to data from a Phase 3 trial. The research, “Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus…
Levels of proteins associated with changes in the inner wall of blood vessels — the endothelium —  are higher in children and adolescents with systemic lupus erythematosus (SLE) and are potential biomarkers of disease activity, as well as of brain and kidney involvement, a study suggests. The study, “…
Higher expression of nine genes may help identify people with systemic lupus erythematosus (SLE) who will respond to treatment with Stelara (ustekinumab) — an approved therapy in inflammatory disorders but not in SLE. At the 2019 American College of Rheumatology (ACR)/Association for Rheumatology Health Professionals (ARHP) Annual Meeting,…
A new public-private initiative brings academic and industry researchers from 15 European countries together in a large-scale effort to understand differences and commonalities in seven immune-mediated and inflammatory diseases, including systemic lupus erythematosus (SLE), to better predict a patient’s response to treatment and likely disease progression. The project, called 3TR (for…
People with systemic lupus erythematosus (SLE) who stop treatment with hydroxychloroquine less than 12 months after its start are at a higher risk of flares than those who continue using it for at least one year, a study suggests. The research, “Outcomes of Systemic Lupus Erythematosus in…
Recent Posts
- Finding our superpower by surviving lupus flares
- Self-injected Saphnelo offers new flexibility for lupus treatment
- Chronic illness, sex, and intimacy: The conversation we’re not having
- Galápagos’ oral therapy for lupus fails to meet key trial objective
- What I learned about navigating travel anxiety with lupus